Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.88 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.88 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.88 |
| ▸ | MEN1 | O00255 | 1/20 | 0.88 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.88 |
| ▸ | DGKA | P23743 | 1/20 | 0.74 |
| ▸ | FAAH | O00519 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | PRKCA | P17252 | 3/20 | 0.59 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.59 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.59 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.59 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.58 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.58 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.58 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.58 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.58 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.58 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.58 |
| ▸ | PAM | P19021 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Behenic Acid SCHEMBL190890 | 1.00 | LMNA (0.88) | LMNAKDM4EDUSP3MEN1KMT2A | |
| Monoctanoin Component B SCHEMBL8394660 | 1.00 | LMNA (0.88) | LMNAKDM4EDUSP3MEN1KMT2A | |
| Decanoic Acid SCHEMBL4663166 | 1.00 | LMNA (0.88) | LMNAKDM4EDUSP3MEN1KMT2A | |
| Glycerol Monolaurate SCHEMBL2241699 | 1.00 | LMNA (0.88) | LMNAKDM4EDUSP3MEN1KMT2A | |
| Palmitic Acid SCHEMBL23850779 | 1.00 | LMNA (0.88) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL1960888 | 1.00 | LMNA (0.88) | LMNAKDM4EDUSP3MEN1KMT2A | |
| Monoctanoin Component A SCHEMBL25311832 | 1.00 | LMNA (0.88) | LMNAKDM4EDUSP3MEN1KMT2A | |
| Nonadecanoic Acid SCHEMBL2028549 | 1.00 | LMNA (0.88) | LMNAKDM4EDUSP3MEN1KMT2A | |
| Glyceryl Monostearate SCHEMBL365822 | 1.00 | LMNA (0.88) | LMNAKDM4EDUSP3MEN1KMT2A | |
| Glyceryl Monostearate SCHEMBL16684813 | 1.00 | LMNA (0.88) | LMNAKDM4EDUSP3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220296560-A1 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION IN POWDER FORMULATION CONTAINING ANTIVIRAL AGENT | DAE HWA PHARMA. CO., LTD. (KR) | 2022-09-22 | — | — | US | claimed |
| US-11116744-B2 | Pharmaceutical composition for oral administration comprising taxane | DAE HWA PHARMA. CO., LTD. (KR) | 2021-09-14 | — | — | US | claimed |
| US-11020370-B2 | Pharmaceutical composition for oral administration comprising high concentration taxane | DAE HWA PHARMA. CO., LTD. (KR) | 2021-06-01 | — | — | US | claimed |
| WO-2020251294-A1 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION IN POWDER FORMULATION CONTAINING ANTIVIRAL AGENT | 대화제약 주식회사 | 2020-12-17 | — | — | WO | claimed |
| US-20200237707-A1 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING TAXANE | DAE HWA PHARMA. CO., LTD. (KR) | 2020-07-30 | — | — | US | claimed |
| US-20200230099-A1 | Stable Pharmaceutical Composition Comprising Zanamivir | DAE HWA PHARMA. CO., LTD. (KR) | 2020-07-23 | — | — | US | claimed |
| US-10653663-B2 | Pharmaceutical composition for oral administration comprising taxane | DAE HWA PHARMA. CO., LTD. (KR) | 2020-05-19 | — | — | US | claimed |
| EP-3326628-B1 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING HIGH CONCENTRATION TAXANE | DAE HWA PHARMA CO LTD (KR) | 2020-03-18 | — | — | EP | claimed |
| US-20190000792-A1 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING HIGH CONCENTRATION TAXANE | DAE HWA PHARMA. CO., LTD. (KR) | 2019-01-03 | — | — | US | claimed |
| EP-3326628-A1 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING HIGH CONCENTRATION TAXANE | Dae Hwa Pharma. Co., Ltd (KR) | 2018-05-30 | — | — | EP | claimed |
| US-20170312244-A1 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING TAXANE | DAE HWA PHARMA. CO., LTD. (KR) | 2017-11-02 | — | — | US | claimed |
| EP-3213746-A1 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING TAXANE | Dae Hwa Pharma. Co., Ltd (KR) | 2017-09-06 | — | — | EP | claimed |
| EP-4701428-A1 | A METHOD FOR PREPARING A FOOD PRODUCT AND A FOOD PRODUCT | Teknologian Tutkimuskeskus VTT OY (FI) | 2026-03-04 | — | — | EP | disclosed |
| US-20260043055-A1 | PRODUCTION OF FATTY ALCOHOLS IN PEROXISOME OF YARROWIA LIPOLYTICA | UNIVERSITY OF DELAWARE (US) | 2026-02-12 | — | — | US | disclosed |
| US-20250101485-A1 | METHODS OF PRODUCING CAROTENOIDS FROM ACID WHEY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2025-03-27 | — | — | US | disclosed |
| WO-2024252067-A1 | A METHOD FOR PREPARING A FOOD PRODUCT AND A FOOD PRODUCT | TEKNOLOGIAN TUTKIMUSKESKUS VTT OY (FI) | 2024-12-12 | — | — | WO | disclosed |
| WO-2006002273-A1 | VISCOUS FAT COMPOSITIONS HAVING LOW AMOUNTS OF TRANS-FAT, METHODS AND PRODUCTS | GENERAL MILLS, INC. (US) | 2006-01-05 | — | — | WO | disclosed |
| US-5376643-A | Treating scalp with mixture containing derivatives of adenosine 3*,5*-cyclic monophosphate to restore original hair color | LION CORPORATION (JP) | 1994-12-27 | — | — | US | disclosed |
| EP-0260697-B1 | COMPOSITION FOR APPLICATION TO HAIR | LION CORPORATION (JP) | 1993-03-17 | — | — | EP | disclosed |
| EP-0260697-A2 | Composition for application to hair | LION CORPORATION (JP) | 1988-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220296560-A1 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION IN POWDER FORMULATION CONTAINING ANTIVIRAL AGENT | LIPC, GK, LIPA | LMNA 3281/4885KDM4E 2113/4885DUSP3 2209/4885 |
| US-20200230099-A1 | Stable Pharmaceutical Composition Comprising Zanamivir | LIPC, PNLIP, LPL | LMNA 4012/4885KDM4E 3535/4885DUSP3 3803/4885 |
| US-20260043055-A1 | PRODUCTION OF FATTY ALCOHOLS IN PEROXISOME OF YARROWIA LIPOLYTICA | FAR1, FASN, ACADM | LMNA 3483/4885KDM4E 1785/4885DUSP3 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.